Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial
Key facts
- Where
- Aalborg, Aarhus N, Copenhagen Oe, Herlev, Odense C, Roskilde és Vejle, DániaSee the 7 sites
- Phase
- 3. fázis
Where in Dánia
- Aalborg University HospitalAalborg, DániaTaking people
- Aarhus University HospitalAarhus N, DániaTaking people
- RigshospitaletCopenhagen Oe, DániaTaking people
- Herlev HospitalHerlev, DániaTaking people
- Odense University HospitalOdense C, DániaTaking people
- Zealand University HospitalRoskilde, DániaTaking people
- Lillebaelt HospitalVejle, DániaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus University Hospital
- Trial code
- EU 2022-502633-26-00
- Record updated
- 2026. július 28.
- Original description
To test if perioperative treatment with TXA is superior to placebo and reduces the early relapse rates by >10%, for patients diagnosed with melanoma undergoing sentinel lymph node biopsy surgery.Read full original descriptionShow less
Perioperative treatment with Tranexamic Acid (TXA) in melanoma; prognostic and treatment related impact of the plasminogen-plasmin pathway
To test if perioperative treatment with TXA is superior to placebo and reduces the early relapse rates by >10%, for patients diagnosed with melanoma undergoing sentinel lymph node biopsy surgery.
Inclusion: Patients: Diagnosed with invasive cutaneous melanoma (pathological stage/tumor grade higher than T2b), defined as either: Breslow thickness >1.0-2.0 mm with presence of ulceration or Breslow thickness >2.0 mm regardless of ulceration status Eligible for surgery (wide local excision and sentinel lymph node biopsy). >/=18 years of age and </=80 years of age Signed Informed Consent Form.
Exclusion: Patients: With prior history of invasive melanoma Thromboembolic events within the last 3 months Pregnancy * Active breast feeding Known allergy or hypersensitivity to TXA Known and treated epilepsia or previous seizures eGFR 0-50.